sulfur hexafluoride has been researched along with Wet Macular Degeneration in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Han, JM; Kang, HG; Kim, JH; Kim, KL; Kim, M; Kim, MS; Kim, SW; Lee, CS; Lee, JY; Park, SJ; Woo, SJ | 1 |
| Guerriero, M; Maggio, E; Mete, M; Peroglio Deiro, A; Pertile, G; Polito, A; Prigione, G; Sartore, M | 1 |
| Arslan, G; Bardak, H; Bardak, Y; Erçalık, Y; Erdem, B; Timlioglu, S | 1 |
| Hirano, Y; Kato, A; Kimura, M; Ogura, Y; Shibata, Y; Uemura, A; Yasukawa, T; Yoshida, M | 1 |
| Chang, W; Garg, SJ; Gupta, SA; Ho, AC; Hsu, J; Maturi, R; Regillo, CD; Sivalingam, A | 1 |
| Cho, HJ; Han, JI; Kim, HS; Kim, JH; Kim, JW; Koh, KM; Lee, TG; Lew, YJ | 1 |
| Byeon, SH; Lee, JM; Shin, JY | 1 |
| Araújo, J; Carneiro, Â; Falcão-Reis, F; Faria, PA; Rocha-Sousa, A; Sousa, C | 1 |
| Barr, CC; Fassbender, JM; Schaal, S; Sherman, MP | 1 |
| Tsymanava, A; Uhlig, CE | 1 |
| Gandorfer, A; Hakim, I; Haritoglou, C; Kampik, A; Mayer, WJ; Ulbig, M; Wolf, A | 1 |
1 trial(s) available for sulfur hexafluoride and Wet Macular Degeneration
| Article | Year |
|---|---|
Flattening of retinal pigment epithelial detachments after pneumatic displacement of submacular hemorrhages secondary to age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Endotamponade; Female; Fibrinolytic Agents; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Intravitreal Injections; Male; Middle Aged; Retinal Detachment; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tissue Plasminogen Activator; Tomography, Optical Coherence; Visual Acuity; Wet Macular Degeneration | 2018 |
10 other study(ies) available for sulfur hexafluoride and Wet Macular Degeneration
| Article | Year |
|---|---|
MACULAR HOLE ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION: Pathogenesis and Surgical Outcomes.
Topics: Aged; Endotamponade; Female; Fluorocarbons; Geographic Atrophy; Humans; Male; Middle Aged; Retinal Perforations; Retrospective Studies; Silicone Oils; Sulfur Hexafluoride; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Vitrectomy; Wet Macular Degeneration | 2021 |
Intravitreal Recombinant Tissue Plasminogen Activator and Sulphur Hexafluoride Gas for Submacular Haemorrhage Displacement in Age-Related Macular Degeneration: Looking behind the Blood.
Topics: Aged; Aged, 80 and over; Choroidal Neovascularization; Combined Modality Therapy; Endotamponade; Female; Fibrinolytic Agents; Fluorescein Angiography; Humans; Intravitreal Injections; Male; Middle Aged; Prone Position; Recombinant Proteins; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tissue Plasminogen Activator; Tomography, Optical Coherence; Visual Acuity; Vitrectomy; Wet Macular Degeneration | 2020 |
Sequential tissue plasminogen activator, pneumatic displacement, and anti-VEGF treatment for submacular hemorrhage.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Combined Modality Therapy; Endotamponade; Female; Fibrinolytic Agents; Fluorescein Angiography; Humans; Intravitreal Injections; Male; Middle Aged; Pilot Projects; Prone Position; Ranibizumab; Retina; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2018 |
Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Air; Angiogenesis Inhibitors; Combined Modality Therapy; Endotamponade; Female; Fibrinolytic Agents; Fluorescein Angiography; Fluorocarbons; Humans; Injections, Intraocular; Male; Middle Aged; Prone Position; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tissue Plasminogen Activator; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitrectomy; Wet Macular Degeneration | 2014 |
Intravitreal ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Coloring Agents; Combined Modality Therapy; Endotamponade; Female; Fluorescein Angiography; Fluorocarbons; Humans; Indocyanine Green; Intravitreal Injections; Male; Middle Aged; Ranibizumab; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2015 |
Anti-vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Endotamponade; Female; Fluorescein Angiography; Fluorocarbons; Follow-Up Studies; Humans; Intravitreal Injections; Male; Ranibizumab; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2015 |
Intravitreal injection of recombinant tissue plasminogen activator in submacular hemorrhage: case series.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Endotamponade; Eye Injuries; Female; Fibrinolytic Agents; Humans; Intravitreal Injections; Male; Middle Aged; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tissue Plasminogen Activator; Treatment Outcome; Visual Acuity; Wet Macular Degeneration; Wounds, Nonpenetrating | 2016 |
TISSUE PLASMINOGEN ACTIVATOR FOR SUBFOVEAL HEMORRHAGE DUE TO AGE-RELATED MACULAR DEGENERATION: Comparison of 3 Treatment Modalities.
Topics: Aged; Aged, 80 and over; Endotamponade; Exudates and Transudates; Female; Fibrinolytic Agents; Fluorocarbons; Fovea Centralis; Humans; Intravitreal Injections; Male; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tertiary Care Centers; Tissue Plasminogen Activator; Tomography, Optical Coherence; Visual Acuity; Vitrectomy; Wet Macular Degeneration | 2016 |
Intravitreal recombinant tissue plasminogen activator without and with additional gas injection in patients with submacular haemorrhage associated with age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Endotamponade; Female; Fibrinolytic Agents; Fluorocarbons; Gases; Humans; Intraocular Pressure; Intraoperative Complications; Intravitreal Injections; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tissue Plasminogen Activator; Visual Acuity; Wet Macular Degeneration | 2012 |
Efficacy and safety of recombinant tissue plasminogen activator and gas versus bevacizumab and gas for subretinal haemorrhage.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Cataract Extraction; Combined Modality Therapy; Endotamponade; Female; Fibrinolytic Agents; Humans; Intravitreal Injections; Male; Pilot Projects; Recombinant Proteins; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tissue Plasminogen Activator; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitrectomy; Wet Macular Degeneration | 2013 |